세계의 자폐증 스펙트럼 진단 시장 예측 - 유형별, 진단 방법별, 서비스별, 연령층별, 유통 채널별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Autism Spectrum Disorder Diagnostics Market is accounted for $29.99 billion in 2025 and is expected to reach $56.61 billion by 2032 growing at a CAGR of 9.5% during the forecast period. Autism Spectrum Disorder (ASD) is diagnosed through a comprehensive evaluation that typically involves developmental screening and a detailed assessment by specialists such as psychologists, neurologists, or developmental pediatricians. The goal of the diagnostic process is to find limited, repetitive patterns of behavior, interests, or activities as well as ongoing challenges with social communication and interaction. Although these symptoms may not be completely noticeable until social demands surpass the person's capacity, they must be present from an early age. Together with feedback from parents, educators, and caregivers, clinicians utilize standardized instruments such as the Autism Diagnostic Observation Schedule and the Autism Diagnostic Interview-Revised.

According to data from the U.S. Centers for Disease Control and Prevention's Autism and Developmental Disabilities Monitoring (ADDM) Network, about 1 in 31 eight-year-old children-approximately 3.2%-were identified with Autism Spectrum Disorder (ASD) in 2022.

Market Dynamics:

Driver:

Growing awareness and prevalence of ASD

One of the main factors propelling the diagnostics market is the increase in diagnoses of autism spectrum disorder worldwide. This growth is a result of improved screening procedures, expanded diagnostic criteria, and increased public and clinical awareness in addition to an actual rise in cases. More referrals for evaluation result from improved early sign recognition by community organizations, healthcare systems, and schools. Furthermore, the market for diagnostic services and tools has grown dramatically as ASD is now actively screened for as part of child development programs in many countries, having previously been a relatively misunderstood condition.

Restraint:

Shortage of trained specialists and service disparities

One of the most important issues in diagnosing ASD is the lack of skilled specialists, such as developmental pediatricians, child psychologists, neurologists, and speech-language pathologists. The diagnostic process necessitates extensive training and interdisciplinary collaboration, but there is a shortage of these specialists, particularly in developing countries and rural areas. Families are consequently frequently faced with lengthy waiting lists, which can last for months or even years. This causes a delay in diagnosis and early intervention services. Because urban areas typically have more resources and specialists, there are glaring differences in the availability of care. Regional disparities in the promptness and quality of diagnosis are exacerbated by the unequal distribution of expertise, which restricts the growth of the entire market.

Opportunity:

Developments in genetic and biomarker research

Promising genetic markers, neuroimaging patterns, and biochemical indicators that have been found through ongoing research into the biological causes of autism have the potential to completely transform diagnostics. Tests based on biomarkers may offer scalable, early, and objective screening techniques that supplement or even outperform behavioral evaluations. Diagnostic techniques can be improved to identify distinct subtypes of autism as scientific knowledge of the etiology of ASD grows, allowing for more specialized intervention approaches. This improves diagnosis precision and dependability while also paving the way for personalized medicine strategies in the treatment of ASD.

Threat:

Concerns about data privacy and ethics

The gathering of sensitive personal and behavioral data, frequently from children, is necessary for many new diagnostic technologies, especially those that use AI, mobile apps, and telehealth platforms. Particularly in areas with stringent laws like the US Health Insurance Portability and Accountability Act (HIPAA) or the EU's General Data Protection Regulation (GDPR), this presents serious questions regarding privacy, consent, and data protection. Confidentiality violations, non-medical data misuse, or ambiguous data ownership could erode public confidence and discourage the use of novel diagnostic techniques. Businesses that neglect to put strong security measures and open privacy policies in place risk legal repercussions as well as harm to their reputation.

Covid-19 Impact:

The COVID-19 pandemic had a mixed effect on the market for diagnostics for autism spectrum disorder (ASD). At first, lockdowns, clinic closures, and limitations on in-person evaluations caused service disruptions, which resulted in delayed diagnoses and long waiting lists globally. Due to safety concerns or limited access to specialists, many families delayed assessments, especially in underserved and rural areas. But the crisis also spurred advancements in AI-based evaluations, digital screening tools, and virtual behavioural observations, as well as a faster uptake of telehealth and remote diagnostic solutions. The pandemic eventually sparked long-term changes by incorporating remote diagnostics into standard practice, improving accessibility for certain populations, and creating new growth opportunities for the market, even though short-term revenues suffered.

The behavioral assessments segment is expected to be the largest during the forecast period

The behavioral assessments segment is expected to account for the largest market share during the forecast period. These tests serve as the foundation for diagnosing ASD because they concentrate on closely observing a person's social interactions, communication abilities, and repetitive behaviors-all of which are key markers of autism. To ensure thorough evaluation, clinicians around the world frequently use standardized tools like the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R), frequently in conjunction with caregiver input. They are very popular because of their non-invasiveness, affordability, and suitability for a range of age groups. Furthermore, behavioral assessments are easily accessible for early screening and intervention because they are intricately woven into the educational and healthcare systems.

The digital assessment tools segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the digital assessment tools segment is predicted to witness the highest growth rate, driven by the quick uptake of cloud-enabled, AI-powered, app-based platforms that allow for remote, scalable, and early screening of behaviors linked to autism. These tools are perfect for use in clinics, schools, and homes because they are affordable, accessible, and provide fast insights. Their adoption has been further accelerated by growing smart phone penetration, rising digital literacy, and the post-pandemic acceptance of telehealth. Moreover, digital assessment tools are revolutionizing ASD diagnostics and establishing themselves as the fastest-growing market in the world by combining real-time data analytics, interoperability with healthcare systems, and user-friendly interfaces.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by widespread adoption of standardized diagnostic procedures, high awareness levels, and sophisticated healthcare infrastructure. The area benefits from substantial insurance coverage for ASD assessments and interventions, as well as robust governmental and nonprofit programs encouraging early screening. Its market dominance is further reinforced by the presence of top diagnostic companies, highly qualified clinical professionals, and access to cutting-edge technologies like genetic testing and AI-based screening tools. Additionally, North America is the world's leading center for ASD diagnostics due to a number of factors, including growing autism prevalence rates, substantial research funding, and solid partnerships between healthcare organizations and academic institutions.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by increased government programs for early screening and intervention, better healthcare infrastructure, and growing awareness of autism. While increasing access to healthcare in rural and semi-urban areas is expanding the patient base, rapid economic growth in nations like China, India, and Japan has resulted in increased investments in diagnostic technologies. Diagnostics are becoming more affordable and accessible due to the growing use of telehealth services and digital assessment tools. Furthermore, the accelerated market growth in this region is also being driven by partnerships between international diagnostic companies and regional healthcare providers, rising prevalence rates, and increased educational outreach.

Key players in the market

Some of the key players in Autism Spectrum Disorder Diagnostics Market include Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Cognoa Inc., Thermo Fisher Scientific Inc., Siemens Healthineers, Invitae Corporation, GE Healthcare, Illumina, Inc., GeneDx, PerkinElmer, Inc., Fulgent Genetics, Charles River Laboratories International, Inc., Myriad Genetics, Inc. and Cortica Inc.

Key Developments:

In July 2025, Agilent Technologies Inc. announced the recent signing of a Memorandum of Understanding (MOU) with the Nanyang Environment & Water Research Institute, outlining their collaboration in advancing environmental and water research over the next three years. NEWRI is a leading research institute at Nanyang Technological University, Singapore, ranked 13th globally for Environmental Sciences by QS World University Ranking in 2025.

In March 2025, F. Hoffmann-LaRoche Ltd and Danish Zealand Pharma A/S have entered into a license agreement to co-develop and co-commercialise Zealand's Phase II long-acting amylin mimetic petrelintide in weight management of overweigt and obese people. Besides petrelintide monotherapy, Zealand will also help co-develop and co-commercialise drug combos such as petrelintide/CT-388, which Roche got in 2023 from the acquisition of Carmot Therapeutics, in the US and Europe.

In December 2024, Abbott Laboratories and DexCom that they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices. The agreement will dismiss all pending cases in courts and patent offices worldwide, along with a provision preventing legal action between the companies for patent and appearance disputes for the next 10 years.

Types Covered:

• Autistic Disorder
• Asperger Syndrome
• Pervasive Development Disorder (PDD)
• Other Types

Diagnostic Methods Covered:

• Behavioral Assessments
• Genetic Testing
• Neuroimaging Techniques
• Biomarker Analysis
• Developmental Screening
• Cognitive Assessment
• Neurological Assessment

Services Covered:

• Clinical Assessments
• Standardized Screening Tools
• Digital Assessment Tools
• Neuropsychological Tests
• Behavioral Approaches
• Early Intervention
• Medication
• Telehealth Services
• Other Services

Age Groups Covered:

• Children (Pediatric)
• Adolescents
• Adults

Distribution Channels Covered:

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Pharmacies

End Users Covered:

• Hospitals
• Diagnostic Centers
• Research Institutes
• Specialty Clinics
• Educational Institutions

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Autism Spectrum Disorder Diagnostics Market, By Type

• 5.1 Introduction
• 5.2 Autistic Disorder
• 5.3 Asperger Syndrome
• 5.4 Pervasive Development Disorder (PDD)
• 5.5 Other Types
  • 5.5.1 Atypical Autism
  • 5.5.2 Childhood Disintegrative Disorder
  • 5.5.3 PDD-NOS

6 Global Autism Spectrum Disorder Diagnostics Market, By Diagnostic Method

• 6.1 Introduction
• 6.2 Behavioral Assessments
• 6.3 Genetic Testing
• 6.4 Neuroimaging Techniques
• 6.5 Biomarker Analysis
• 6.6 Developmental Screening
• 6.7 Cognitive Assessment
• 6.8 Neurological Assessment

7 Global Autism Spectrum Disorder Diagnostics Market, By Service

• 7.1 Introduction
• 7.2 Clinical Assessments
• 7.3 Standardized Screening Tools
• 7.4 Digital Assessment Tools
• 7.5 Neuropsychological Tests
• 7.6 Behavioral Approaches
• 7.7 Early Intervention
• 7.8 Medication
• 7.9 Telehealth Services
• 7.10 Other Services

8 Global Autism Spectrum Disorder Diagnostics Market, By Age Group

• 8.1 Introduction
• 8.2 Children (Pediatric)
• 8.3 Adolescents
• 8.4 Adults

9 Global Autism Spectrum Disorder Diagnostics Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Hospital Pharmacies
• 9.3 Drug Stores and Retail Pharmacies
• 9.4 Online Pharmacies

10 Global Autism Spectrum Disorder Diagnostics Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Diagnostic Centers
• 10.4 Research Institutes
• 10.5 Specialty Clinics
• 10.6 Educational Institutions

11 Global Autism Spectrum Disorder Diagnostics Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Agilent Technologies Inc.
• 13.2 F. Hoffmann-La Roche Ltd.
• 13.3 Abbott Laboratories
• 13.4 Cognoa Inc.
• 13.5 Thermo Fisher Scientific Inc.
• 13.6 Siemens Healthineers
• 13.7 Invitae Corporation
• 13.8 GE Healthcare
• 13.9 Illumina, Inc.
• 13.10 GeneDx
• 13.11 PerkinElmer, Inc.
• 13.12 Fulgent Genetics
• 13.13 Charles River Laboratories International, Inc.
• 13.14 Myriad Genetics, Inc.
• 13.15 Cortica Inc.